Report from Annual General Meeting of Re:NewCell AB on 16 May 2023 - Seite 2

Authorization for the Board of Directors to resolve upon issues of shares, warrants and/or convertible instruments
The Annual General Meeting resolved to authorize the Board of Directors to, on one or several occasions until the next Annual General Meeting, with or without preferential rights for the shareholders, resolve upon issues of shares, warrants and/or convertible instruments. The total number of shares that may be issued under the authorization (including any new shares following exercise or conversion of warrants or convertible instruments issued under the authorization) may correspond to an increase of the share capital by no more than ten percent at the time the authorization is used for the first time. Resolutions by support of the authorization may include provisions on non-cash, set-off or cash payment.

The purpose of the authorization and the reasons for any deviation from the shareholders' preferential rights is that issues should be able to take place in order to increase the Company's financial flexibility and the Board of Director's room for maneuver. To the extent than an issue by support of the authorization takes place with deviation from the shareholders' preferential rights, the issue shall take place on market terms.

Resolution on principles for appointment of a Nomination Committee
The Annual General Meeting resolved to adopt the proposed principles for the appointment of a Nomination Committee.

Resolution on adoption of a warrant-based incentive program for a maximum of two new key persons
The Annual General Meeting resolved to adopt a warrant-based incentive program for a maximum of two new key persons in the Company by way of (A) a resolution on an issue of no more than 40,000 warrants of series 2023/2026 to the Company, and (B) a resolution on approval of transfer of warrants of series 2023/2026 from the Company to a maximum of two new key persons in the Company. The warrants are issued free of charge to the Company and shall be transferred to the new key persons on market terms at a price established in accordance with a calculated market value for the warrants by application of Black & Scholes valuation model. Each (1) warrant entitles to subscription of one (1) share in the Company during the period commencing on 1 December 2026 (however not earlier than the day after the publication of the Company's interim report for the period Q3 2026) up to and including the date that falls 30 calendar days thereafter. Under the terms and conditions of the warrants, the period during which the warrants may be exercised may be extended if participants are prevented from exercising their subscription rights due to applicable laws on insider trading or any equivalents. The subscription price for each new share subscribed by support of the warrants shall be determined to an amount equivalent to 160 percent of the volume-weighted average price of the Company's share on Nasdaq First North Premier Growth Market during the period of ten trading days immediately preceding the offer to subscribe for warrants, rounded to the nearest full ten cents (Sw. öre) whereby five cents shall be rounded up. However, the subscription price shall not be less than the share's quota value. Upon full exercise of the warrants the Company's share capital will increase by SEK 1,020.90. The complete terms and conditions for the warrants are available on the Company's website, www.renewcell.com. As set forth in the terms and conditions for the warrants, the subscription price and the number of shares that each warrant entitles to subscription of may be recalculated in certain cases.